Compare Incyte Corporation (INCY) vs Vistra Corp (VST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Vistra Corp — how do they compare? Incyte Corporation trades at $120.55 (market cap $24.48B), while Vistra Corp trades at $146.48 (market cap $49.23B). The key difference: Vistra Corp is far larger — about 2× Incyte Corporation's market cap, and Vistra Corp pays a 0.63% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | VST | |
|---|---|---|
Market Cap | $24.48B | $49.23B |
Sector | Health | Technology |
52-Week High | $129.93 | $217.92 |
52-Week Low | $81.66 | $134.71 |
Enterprise Value | $19.98B | $71.17B |
Dividend Yield | — | 0.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.52, down 0.45% on the day but maintains strong momentum with a 23% gain year-to-date in 2026. The stock shows bullish technical signals with moving averages supporting upward trends, while recent Q2 2026 earnings beat expectations with EPS of $3.09 versus $2.15 estimate. Revenue growth continues with 2025 reaching $5.14B and projected 2026 revenue of $5.8B, supported by strong product sales including Jakafi and Opzelura.
Outlook remains positive with analyst consensus price target of $122.82 representing 1.9% upside potential. Key opportunities include continued revenue growth and recent EU approval for Opzelura, while risks involve competitive pressures and the stock's proximity to 52-week highs. The company's strong profitability metrics with 27.71% net margin and 30.67% ROE support fundamental strength.
Vistra Corp (VST) trades at $146.68, up 1.21% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beat ($2.87 vs $1.32 expected) but missed Q4 2025 and Q2 2026 estimates, reflecting volatile performance. Fundamentals show impressive ROE of 75.73% and net income margin of 11.55%, though valuation metrics remain elevated with P/E of 24.74. Recent news highlights Vistra's positioning in the data center power boom despite ERCOT market softness.
Vistra presents a compelling growth story driven by data center electricity demand, with 91% analyst buy ratings and $239.75 price target suggesting 63% upside. However, execution risks from volatile energy markets and high valuation multiples warrant caution. The stock offers exposure to AI infrastructure growth but faces headwinds from hedging losses and competitive pressures in power markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Vistra Corp
Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →
